Novartis, Regeneron Cardio Results Pump Up Wall St.
Wall Street rewarded Novartis and Regeneron Tuesday for presentations at a cardiology conference over the weekend, with Novartis’ heart-failure drug hailed as a potential game-changer. At the European Society of Cardiology (ESC) Congress in Barcelona, Novartis (NVS) revealed results of a phase three trial of patients suffering heart failure with reduced ejection fraction. (Ejection fraction is a measure of how much blood a heart